HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

States Cloud US CBD Supplement Market With Patchwork Of Laws While Waiting For FDA To Act

Executive Summary

Legislation some states have passed is unclear and sometimes conflicts with state enforcement agencies’ policies, attorneys commented during recent FDLI conference. In states without a law, many marketers incorrectly assume sales of hemp-derived CBD in those states are legal under the 2018 farm bill.

You may also be interested in...



State Regulation Of Hemp-Derived Cannabinoids Production, Sales? New York Proposes A Model

New York proposal for packaging and testing hemp-derived cannabinoids could be ‘de facto’ standard for other stat, say attorneys tracking the patchwork of state laws. The proposal sets per-product concentration limits and includes licensing fees for processors and retailers.

Unpublished And Under Review? US FDA’s CBD Policy Draft Guidance Still Has Industry Talking

Supplements containing hemp-derived cannabidiols aren’t typical products subject to FDA’s regulatory oversight, and the document stating its thinking on enforcement in the market submitted to the Office of Management and Budget isn’t a typical draft guidance.

Drug Claims For CBD, Detoxification Supplements Make Warning List Along With Pandemic Fraud

Latest warning letters published by FDA include not only two more about claims for supplements to prevent or treat the disease caused by the novel coronavirus, but also warnings about good manufacturing practices violations and noncompliant claims for CBD-containing products and for a detoxification line.

Related Content

Topics

UsernamePublicRestriction

Register

RS150568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel